Skip to main content
STE logo

STE · STERIS plc

Track STE — free
$256.89 -0.53 (-0.20%)
Market Cap
$25.00B
Shares
97.11M
Volume · Nov 18 81.04K Avg daily vol (3M) 721.18K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$257.41 Open$259.32 Day$256.88–262.50 52W close$199.40–268.65 Avg vol 30d811K Short int2.2M · 2.2% of shares · 2.9d Short vol68% Last earningsNov 5, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 5

Up next

Feb 4, 2027 Est · unconfirmed · in 11 wks

Latest documents

2026
Nov 12
Current report 8-K Events of Nov 9
$1.5 billion notes priced to fund Xodus Medical acquisition

STERIS Irish FinCo Unlimited Company, STERIS plc’s wholly-owned subsidiary, priced $1.5 billion of senior notes: $750 million due 2033 at 5.650% and $750 million due 2036 at 5.875%. Proceeds will help fund the pending Xodus Medical, Inc. acquisition.

Other events Read from the first part of this long document
2 source passages
On November 9, 2026, STERIS Irish FinCo Unlimited Company, a public unlimited company incorporated under the laws of Ireland (the “Issuer”) and a wholly-owned subsidiary of STERIS plc, a public limited company incorporated under the laws of Ireland (the “Company” and, together with its consolidated subsidiaries, “STERIS”), priced an offering (the “Offering”) of $1.5 billion in aggregate principal amount of senior notes, consisting of $750 million aggregate principal amount of senior notes due 2033 (the “2033 Notes”) and $750 million aggregate principal amount of senior notes due 2036 (the “2036 Notes” and together with the 2033 Notes, the “Notes”). The 2033 Notes will bear interest at a rate of 5.650% per annum and the 2036 Notes will bear interest at a rate of 5.875% per annum. The Company intends to use the net proceeds from the Offering, together with borrowings under the delayed draw term loan agreement, dated November 4, 2026, among the Issuer and the Guarantors, the lenders party thereto and J.P. Morgan SE, as administrative agent, and cash on hand, to fund the purchase price of the pending acquisition of Xodus Medical, Inc. and certain related entities (the “Acquisition”), transaction expenses, general corporate expenses and working capital needs. Open the document at this passage
Nov 6
Registration statement S-3ASR
Registers flexible shelf for debt and equity offerings

STERIS plc and certain subsidiaries registered a shelf for debt securities, guarantees, ordinary and preferred shares, warrants, and units, to be sold in future offerings. Net proceeds are expected for general corporate purposes, with final terms set in prospectus supplements.

Read from the first part of this long document
3 source passages
STERIS plc or any of its subsidiaries listed above may from time to time offer and sell any of the securities identified above, or any combination thereof, in each case, in one or more series and in one or more offerings. STERIS plc or any of its subsidiaries listed above will provide the specific terms of the securities to be offered in one or more supplements to this prospectus. Unless we inform you otherwise in the applicable prospectus supplement, we expect to use the net proceeds from the sale of our securities to which this prospectus relates for general corporate purposes. Open the document at this passage
Nov 5
Earnings call
Q2 Adjusted EPS Rises 19% to $2.94; Outlook Raised to $11.35-$11.55

STERIS reported second-quarter adjusted earnings per diluted share of $2.94, up 19% from $2.47, helped by about $20 million of tariff refunds. The company raised its fiscal 2027 adjusted EPS outlook to $11.35 to $11.55 from $11.10 to $11.30, and said the outlook excludes the pending Exodus Medical acquisition.

4 source passages
Adjusted earnings per share were $2.94, a 19% increase over $2.47 in the second quarter of last year. Our fiscal 2027 earnings per diluted share outlook has been increased to $11.35 to $11.55, compared with our prior range of $11.10 to $11.30. Margin expansion was driven primarily by tariff refunds of approximately $20 million during the quarter, which added 130 basis points year over year. But as a reminder, this outlook does not include Exodus Medical, and we will update our expectations after close. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2027 Q2, ended Sep 30
Xodus Medical acquisition valued at $2.1 billion

STERIS agreed to acquire Xodus Medical for approximately $2.1 billion in cash at closing, plus potential earnout consideration of up to $150.0 million, and expects to close by December 31, 2026.

Revenue $1.59B ▲ 8.8% Net income $213.7M ▲ 11.4%
Read from the MD&A section
Source passage
On October 11, 2026, we entered into the Purchase Agreement to acquire Xodus Medical for approximately $2.1 billion in cash at closing, subject to customary adjustments, plus potential earnout consideration of up to $150.0 million. We expect to close the Xodus Medical Acquisition by December 31, 2026, subject to customary closing conditions and regulatory approvals. Open the document at this passage
Nov 4
Current report 8-K
$1,600 million revolver and $500 million acquisition loan

On November 4, 2026, STERIS plc entered a $1,600 million revolving credit facility, replacing the October 7, 2024 agreement, and arranged up to $500 million of delayed-draw term financing contingent on the Xodus Medical, Inc. acquisition closing.

Entered into a material agreement, Ended a material agreement, New debt or off-balance-sheet obligation Read from the first part of this long document
3 source passages
On November 4, 2026, STERIS plc (“STERIS”), STERIS Corporation (“Corporation”), STERIS Limited (“Limited”) and STERIS Irish FinCo Unlimited Company (“FinCo”), each as a borrower and guarantor, entered into a credit agreement (the “New Revolving Credit Agreement”) with various financial institutions and each of J.P. Morgan SE and JPMorgan Chase Bank, N.A., as administrative agents, providing for a $1,600 million revolving credit facility (the “Revolver”), which replaces the existing credit agreement, dated as of October 7, 2024 (the “Existing Revolving Credit Agreement”). On November 4, 2026, FinCo, as borrower, and each of STERIS, Corporation and Limited, as guarantors, entered into a new delayed draw term loan credit agreement (the “Delayed Draw Term Loan Agreement”) with various financial institutions and J.P. Morgan SE, as administrative agent, which provides for a delayed draw term loan facility in the amount of up to $500 million (the “Delayed Draw Term Loan”). The Delayed Draw Term Loan cannot be utilized unless, among other conditions, the acquisition of Xodus Medical, Inc. (the “Xodus Medical Acquisition”) is consummated, and the commitments under such Delayed Draw Term Loan will terminate if the Xodus Medical Acquisition is validly terminated or the specified outside date occurs, among other customary conditions. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$6.17B
Trailing 12 months
Net income (TTM)
$826.80M
Trailing 12 months
Revenue growth YoY
+8.8%
Year over year
Operating margin
19.0%
Trailing 12 months
P / E (TTM)
32.5
Trailing earnings · reciprocal yield 3.1%
FCF yield
3.7%
TTM · current market cap
Return on invested capital
10.0%
Trailing 12 months
Net cash
−$1.36B
Latest balance sheet
Dividend yield
1.3%
Trailing 12 months
Shares change YoY
-1.2%
Year over year · fewer shares
Price change (1Y)
+0.2%
Trailing year
Short interest
2.2%
Latest settlement · 2.9 days to cover
View all 125 metrics

AI Brief

Q2 FY27 earnings call · Nov 5, 2026
Q2 FY27

TL;DR. Adjusted EPS rose 19% to $2.94 and the fiscal 2027 adjusted EPS outlook was raised to $11.35 to $11.55, with Life Sciences growth outlook raised to 9% to 10%. Healthcare EBIT margin fell 110 basis points, while six-month free cash flow declined to $492.5 million.

Bullish
  • + Second-quarter total revenue rose 9% to $1.6 billion. new
  • + Adjusted EPS rose 19% to $2.94 in the second quarter.
  • + Life Sciences constant currency organic growth outlook raised to 9% to 10% from 6% to 7%. new
  • + Fiscal 2027 adjusted EPS outlook raised to $11.35 to $11.55 from $11.10 to $11.30. new
  • + Recently announced agreement to acquire Exodus Medical, a surgical specialties products business. new
  • + Life Sciences segment margin reached a record 44.4%, up about 310 basis points. new
Bearish
  • − Underlying margins were down slightly; the quarter's margin gain was driven mainly by approximately $20 million of tariff refunds. new
  • − Healthcare EBIT margin fell 110 basis points to 24%. new
  • − AST segment margin fell about 60 basis points to 44.7%. new
  • − Six-month free cash flow declined to $492.5 million from $527.7 million. new
  • − Life Sciences backlog was $93 million at quarter end, down from the prior year. new
  • − AST constant currency organic growth outlook lowered to 6% to 7% from 7% to 8%. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Moderate
Market backdrop VIX 25.5 · fear Equity put/call 0.71
Technical
price trend
Strong Buy
50 / 200-day cross Golden cross
Price vs 200-day avg +15%
above
Price vs 50-day avg +15%
above
RSI (14) 66
neutral
MACD trend Positive
52-week position 84%
mid-range
Momentum
relative strength
Very Strong
1-month return +14%
trailing
6-month return +20%
trailing
YTD return +2%
this year
Relative strength +22%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) Golden cross
50d $225 › 200d $224 — 50d above 200d
Institutional flow Distributing
-3% holders QoQ · +81 funds added
Insider flow Distributing
Net -$3.3M over 90 days · 100% sells
Short interest Falling
2.25% of shares out · ▼ -9.0% MoM · 2.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
819 holders — mid 3-yr range
Squeeze score 47
elevated · 0–100
Fundamentals
Excellent
Revenue growth +9%
Y/Y
Gross margin 44%
expanding
EPS growth +28%
Y/Y
Free cash flow $972.4M
Valuation P/E 32.5
in line
Buyback $800.0M
remaining
Balance sheet $1.5B
net debt
Quant / Vol
risk profile
Moderate
Volatility 27%
annualized · 1-yr
Max drawdown −26%
past year
ATR 2.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 0 of last 5
Latest guidance · from the 8-K filed Nov 4, 2026
Adjusted earnings per diluted share · fiscal 2027 Non-GAAP Raised $11.35 – $11.55
Aug 5, 2026 $11.10 – $11.30 changed to Nov 4, 2026 $11.35 – $11.55
As reported revenue growth · fiscal 2027 7% – 8%
Constant currency organic revenue growth · fiscal 2027 Non-GAAP 6% – 7%
Healthcare constant currency organic revenue growth · fiscal 2027 Non-GAAP Initiated 6% – 7%
Applied Sterilization Technologies constant currency organic rev · fiscal 2027 Non-GAAP Initiated 6% – 7%
Previous outlook earlier release · from the 8-K filed May 11, 2026

Still-open targets the latest release did not restate under the same label.

Net income from continuing operations per diluted share · fiscal 2027 $9.00 – $9.20
Effective tax rate · fiscal 2027 25%
Prior guidance period ended · from the Earnings Call filed Feb 5, 2026
As-reported revenue growth · fiscal 2026 8% – 9%
Constant currency organic revenue growth · fiscal 2026 7% – 8%
Free cash flow · fiscal 2026 $850M
Earnings per diluted share · fiscal 2026 $10.15 – $10.30
CapEx · fiscal 2026 $375M
Guided vs delivered · last 5 settled
Earnings per diluted share fiscal 2026
guided $10.15 – $10.30
$7.93 Miss −22.4%
Net income from continuing operations per diluted share Twelve Months Ended March 31, 2025
guided $6.55 – $6.75
$6.20 Miss −6.8%
Net income per diluted share Twelve Months Ended March 31, 2023
guided $5.42 – $5.62
$1.07 Miss −80.6%
Net income per diluted share Twelve Months Ended March 31, 2022 (Outlook)
guided $3.12 – $3.22
$2.48 Miss −21.8%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 2 · 4
50 / 200-day cross
Golden cross Bullish
Price vs 200-day avg
+15% Bullish
Price vs 50-day avg
+15% Bullish
RSI (14)
66 Neutral
MACD trend
Positive Bullish
52-week position
84% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) Golden cross
50d $225 › 200d $224 — 50d above 200d
Institutional flow Distributing
-3% holders QoQ · +81 funds added
Insider flow Distributing
Net -$3.3M over 90 days · 100% sells
Short interest Falling
2.25% of shares out · ▼ -9.0% MoM · 2.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
819 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $199 Now $257 · 84% Range high $269
vs 200-day avg +15% vs 50-day avg +15% 50-day above 200-day golden cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Capital expenditures $87.5M the first three months of fiscal 2027 filing —
Debt-to-total capital ratio 20.9% the three months ended June 30, 2026 filing —
Adjusted Income from Operations non-GAAP $354.8M Three Months Ended June 30, 2026 —
GAAP → non-GAAP reconciliation
GAAP Income from Operations 285.8M
+65.3M Amortization of acquired intangible assets
+1.5M Acquisition and integration related charges
+0.3M Tax restructuring costs
+1.8M Amortization of inventory and property "step up" to fair value
+0M Restructuring charges
= Adjusted Income from Operations 354.8M
Adjusted Income Tax Rate non-GAAP 25.9% Three Months Ended June 30, 2026 —
Adjusted Income, net of income tax non-GAAP $254.3M Three Months Ended June 30, 2026 —
AST Constant Currency Organic Growth non-GAAP 4.7% Three Months Ended June 30, 2026 —
AST Organic Growth non-GAAP 5.8% Three Months Ended June 30, 2026 —
Constant Currency Organic Growth non-GAAP 6.2% Three Months Ended June 30, 2026 —
Constant currency organic revenue growth non-GAAP 6% first quarter of fiscal 2027 —
Corporate Operating Loss -$110.1M Three Months Ended June 30, 2026 —
GAAP → non-GAAP reconciliation
GAAP Cash flows from operating activities 367.1M
-87.5M Purchases of property, plant, equipment, and intangibles, net
+0M Proceeds from the sale of property, plant, equipment, and intangibles
= Free Cash Flow 279.6M
Healthcare Backlog $444M Three Months Ended June 30, 2026 —
Healthcare Constant Currency Organic Growth non-GAAP 6.4% Three Months Ended June 30, 2026 —
Life Sciences Backlog $109.9M Three Months Ended June 30, 2026 —
Life Sciences Constant Currency Organic Growth non-GAAP 7.9% Three Months Ended June 30, 2026 —
Life Sciences Organic Growth non-GAAP 8.6% Three Months Ended June 30, 2026 —
Organic Growth non-GAAP 6.8% Three Months Ended June 30, 2026 —
Total Backlog $553.9M Three Months Ended June 30, 2026 —
U.S. GAAP Growth 7.3% Three Months Ended June 30, 2026 —
Employee turnover rate 13% fiscal 2026 filing —
Lost-time Incident Rate 0.32 Fiscal 2026 filing —
Ordinary shares repurchased 0.9M fiscal 2026 filing —
Total constant currency organic growth non-GAAP 7.3% fiscal 2026 filing —
Total employees 17,937 Fiscal 2026 filing —
Total income from operations before adjustments (AST) $524.7M Year Ended March 31, 2026 filing —
Total income from operations before adjustments (Healthcare) $1.04B Year Ended March 31, 2026 filing —
Total income from operations before adjustments (Life Sciences) $251M Year Ended March 31, 2026 filing —
Total organic growth non-GAAP 8.7% fiscal 2026 filing —
Total Recordable Incident Rate 1.03 Fiscal 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
STE
STERIS plc
this stock
$25.00B +1.5% +8.7% 32.5 2.2%
ABT
Abbott Laboratories
$181.35B -16.4% +5.7% 39.1 1.1%
MDT
Medtronic plc
$130.88B +6.5% +8.4% 25.2 1.8%
SYK
Stryker Corp
$120.88B -9.7% +11.2% 33.8 1.7%
BSX
Boston Scientific Corp
$62.37B -54.9% +12.5% 18.2 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
819
% held
97.5%
Net QoQ
-146.1K sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
270
View
Short & Settlement
Short Interest Falling
Shares short
2.2M
Days to cover
2.9d
Change
-216.7K sh
View
Short Volume
Short vol %
68%
As of
Nov 17, 2026
Short Total
View
Fails to Deliver
FTD shares
142
Value
$29.8K
As of
Oct 8, 2026
View
Off-Exchange
Off-exchange %
40.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$3.3M
Buyers / Sellers
0 / 3
Buyers Sellers
View
Congressional Trades Sell
Member
Kevin Hern
Amount
$15.0K–$50.0K
Traded
Sep 15, 2026
View
Financials
Financials
Revenue (FY)
$5.9B
Net income (FY)
$782.3M
EPS diluted
$7.93
View
Buybacks
Authorized
$1.0B
Remaining
$800.0M
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 12, 2026
This year
20

STERIS Irish FinCo Unlimited Company, STERIS plc’s wholly-owned subsidiary, priced $1.5 billion of senior notes: $750 million due 2033 at 5.650% and $750 million due 2036 at 5.875%. Proceeds will help fund the pending Xodus Medical, Inc. acquisition.

View
Proposed Sales
Value
$532.0K
Shares
2.0K
Filed
Nov 13, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
STERIS Announces Financial Result…
Published
Nov 4, 2026
View

Performance

5D 20D 120D MTD YTD
STE +0.1% +14.3% +19.5% +13.3% +1.5%
SPY -2.3% -4.8% -2.9% -3.1% +7.4%
vs SPY +2.4% +19.1% +22.4% +16.4% -5.9%

Capital returns

Latest dividend
$0.69 / share · ex Nov 17, 2026
Raised 9.5%
Paid (TTM)
$2.64 / share · 4 payouts
Dividend yield (TTM, derived)
1.03%
Full dividend history
Buyback program · as of Sep 30, 2026
Authorized
$1.00B
Spent (derived)
$200.00M
Remaining
$800.00M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1757898 CUSIP G8473T100 13F (30d) 787 filings 741 filers Visit website Investor relations